



Practitioner Docket No. 2000DE443

RECEIVED

JUL 28 2003

TECH CENTER 2000/2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Peter KLUG, et al.

Application No.: 10/003,656

Group No.: 1617

#12

AKD

10/16/03

Filed: November 29, 2001

Examiner: Wells, Lauren Q.

For: COSMETIC COMPOSITIONS COMPRISING ALK(EN)YLSUCCINIC ACID DERIVATIVES

MAIL Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22202

Match and Return

INFORMATION DISCLOSURE STATEMENT

CERTIFICATION UNDER 37 C.F.R. Sections 1.8(a) and 1.10*
(When using Express Mail, the Express Mail label number is mandatory;
Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22202.

37 C.F.R. section 1.8(a)


37 C.F.R. section 1.10*

with sufficient postage as first class mail.

as "Express Mail Post Office to Address"
Mailing Label No. _____ (mandatory)

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office (703) _____.
Date: 7-22-03


Signature
Vicki Sgro
(type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b).

"Since the filing of correspondence under [section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Dear Sir:

In accordance with the duty of disclosure provisions of 37 CFR §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the subject application. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than search report(s) from a counterpart foreign application or a PCT International Search Report, if submitted herewith).

1. Enclosures accompanying this Information Disclosure Statement are:
 - 1a. Form PTO-1449.
 - 1b. Copies of Information Disclosure Statement citations.
 - 1c. EPO Search Report
 - 1d. English language translation (complete or relevant portion(s) for each non-English language publication)
2. This Information Disclosure Statement is filed under 37 CFR §1.97(b) with the filing of the U.S. patent application. Accordingly, no fee or §1.97(e) Statement is required.
3. This Information Disclosure Statement is filed under 37 CFR §1.97(b) before the latter of three months after the U.S. patent application filing date or the first Office Action on the merits. Accordingly, no fee or §1.97(e) Statement is required.
4. This Information Disclosure Statement is filed under 37 CFR §1.97(c) after the first Office Action on the merits, but before a Final Office Action or a Notice of Allowance. The \$180.00 fee set forth in 37 CFR §1.17(p) in accordance with 37 CFR §1.97(c) is to be charged to Deposit Account No. 03-2060.

5. This Information Disclosure Statement is filed under 37 CFR §1.97(e) in that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Accordingly, no fee is required.
6. This Information Disclosure Statement is filed under 37 CFR § 1.97(d) after the Final Office Action or the Notice of Allowance, but before payment of the Issue Fee with the filing of a Request For Continued Examination(RCE). Accordingly, no fee or §1.97(e) Statement is required.
7. This is a continuation/divisional application under 37 CFR §1.53(d). The Issue Fee has not been paid.
8. In accordance with 37 CFR §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is enclosed as abstracts in the English language.

Respectfully submitted,



Richard P. Silverman
Agent for the Applicant
Registration No. 36,277

Customer Number 25, 255

Clariant Corporation
Industrial Property Department
4000 Monroe Road
Charlotte, North Carolina 28205
Telephone: 704/331-7156
Facsimile: 704/331-7707

